<DOC>
	<DOCNO>NCT00712530</DOCNO>
	<brief_summary>- DermaVir plasmid DNA-containing synthetic nanomedicine . It administer topically DermaPrep target Langerhans cell . Langerhans cell DermaVir migrate lymph node express HIV-like particle induce immune response kill HIV-infected cell . - Hypothesis : Single DermaVir immunization safe immunogenic measure induction HIV-specific precursor/memory T cell response . - GIHU004 phase I dose escalation study conduct Hungary . It evaluate safety immunogenicity three dose regimen topical DermaVir immunization treatment HIV-infected individual fully suppressive highly active antiretroviral therapy ( HAART ) .</brief_summary>
	<brief_title>Single DermaVir Immunization HIV-1 Infected Patients HAART</brief_title>
	<detailed_description>This study enrol nine HIV-infected adult subject three sequential dose cohort . All durable suppression HIV-RNA HAART previous 6 month CD4 count 300 cells/mm3 . Subjects , receive study Day 0 single DermaVir immunization : - Low dose : 0.1 mg pDNA , 0.8 mL DermaVir administer two DermaPrep patch . - Medium dose : 0.4 mg pDNA , 3.2 mL DermaVir administer four DermaPrep patch . - High dose : 0.8 mg pDNA , 6.4 mL DermaVir administer eight DermaPrep patch . Subjects study total 28 day follow post-treatment safety follow-up 48 week . HAART interrupt . All subject complete 28-day treatment 48 week safety follow phase .</detailed_description>
	<mesh_term>HIV Infections</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Ability willingness subject legal guardian/representative give write informed consent HIV1 infection , document licensed ELISA test kit confirm Western blot , HIV1 culture , HIV1 antigen , plasma HIV1 RNA , second antibody test method ELISA On stable antiretroviral regimen without change interruption least 12 week prior study entry Plasma HIV1 RNA level le 50 copies/mL , obtain least twice within 12 week prior study entry Peak plasma HIV1 RNA level initiation HAART &gt; 1000 copies/mL CD4 cell count &gt; 300 cells/mm3 within 12 week prior study entry Nadir ( low ) CD4+ cell count &gt; 250 cells/mm3 time prior study entry The following laboratory value , obtain within 30 day prior study entry : Absolute neutrophil count ( ANC ) &gt; 1000/mm3 Hemoglobin &gt; 9.0 g/dL Platelet count &gt; 50,000/mm3 Serum creatinine &lt; upper limit laboratory normal range ( ULN ) AST ( SGOT ) , ALT ( SGPT ) , alkaline phosphatase &lt; 2.5 x ULN Total bilirubin &lt; 2.5 x ULN Antinuclear antibody ( ANA ) titer 1:40 lower negative serum antidoublestranded DNA antibody ( antidsDNA ) test result screen . All woman reproductive potential must negative urine betaHCG pregnancy test perform within 14 day prior study entry . Female study volunteer reproductive potential whose male partner undergone successful vasectomy eligible without require use contraception . Acceptable documentation menopause , sterilization , azoospermia write oral documentation communicate clinician . All subject must participate conception process ( e.g . active attempt become pregnant impregnate , sperm donation , vitro fertilization ) , participate sexual activity could lead pregnancy , study volunteer/ partner must use two reliable method contraception simultaneously receive protocolspecified vaccination 3 month last vaccination . Karnofsky performance score &gt; 90 within 30 day prior study entry Men woman age 1850 year Viral load measurement &gt; 50 copies/mL within last 12 week prior study entry History evidence active skin disease ( e.g . atopic dermatitis ) , chronic autoimmune disease significant active skin disease Treatment topical corticosteroid close proximity propose vaccination sit within 2 week prior study entry Excessive exposure sun ( e.g . sunbathe ) within 2 week prior study entry Use local skin treatment target vaccination site within 7 day prior study entry History diabetes bleed disorder Previous CDC category C event Pregnancy breastfeeding Use immunomodulating therapy , include cyclosporin , IgGcontaining product , interleukin , interferon , systemic glucocorticosteroids , exposure experimental HIV vaccine within 6 month prior study entry Receipt vaccine within 30 day prior study entry Allergy/sensitivity study vaccine product , include adhesive , exclude Active drug alcohol use dependence Serious illness subject either complete therapy clinically stable therapy , opinion site investigator , least 14 day prior study entry Hepatitis B surface antigen and/or antihepatitis C positive</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>February 2013</verification_date>
	<keyword>HIV</keyword>
	<keyword>Vaccine</keyword>
	<keyword>Immune Therapy</keyword>
	<keyword>DermaVir</keyword>
</DOC>